Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06335914
Other study ID # dualPET-mPC
Secondary ID CAPCR: 23-5595
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date September 4, 2029

Study information

Verified date March 2024
Source University Health Network, Toronto
Contact Di (Maria) Jiang, M.D.
Phone 416-946-4501
Email di.jiang@uhn.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date September 4, 2029
Est. primary completion date March 4, 2029
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male, age = 18 years - Histologically or cytologically confirmed prostate cancer (adenocarcinoma) - Poor risk patients with mCSPC at study enrollment - De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI - High or low volume mCSPC plus PSA =4.0 after 6-8 months of initiating ADT - Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center. - No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study - Patients enrolled in clinical trials are eligible if they satisfy all other criteria of eligibility Exclusion Criteria: - Under a randomized-controlled trial with unknown allocation of systemic therapy - Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams - Unable to provide written consent by patient and their legal representatives - In the opinion of the treating physician: - conditions which would significantly impair the patient's ability to comply with study procedures and follow up - Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging - another active malignancy - patient on dialysis - another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Ga 68 PSMA-11 PET
Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
18F-DCFPyL PET
Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
FDG PET
Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.

Locations

Country Name City State
Canada Princess Margaret Cancer Centre Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with high volume mCSPC having PSMA avid disease 5 years
Secondary Proportion of patients with PSMA-/FDG+ discordant lesions 5 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06006104 - Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Recruiting NCT03936218 - Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer Phase 3
Completed NCT02234089 - Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Completed NCT01078545 - Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS) N/A
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Recruiting NCT05942001 - Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1
Active, not recruiting NCT04117594 - Whole Body Magnetic Resonance Imaging Study
Not yet recruiting NCT06369246 - PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer Phase 2
Completed NCT01383863 - A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
Completed NCT03651271 - Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer Phase 2
Active, not recruiting NCT05590793 - Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Phase 3
Recruiting NCT06095089 - A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer Phase 1
Active, not recruiting NCT02362620 - PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
Active, not recruiting NCT02787837 - PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
Recruiting NCT05800665 - A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer Phase 1
Recruiting NCT03938649 - SRAM study_Postate Cancer Phase 2
Completed NCT00871585 - Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide N/A
Active, not recruiting NCT02922218 - PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
Terminated NCT03577028 - Study of HPN424 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Terminated NCT03971110 - A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. Phase 4